IDS and mucopolysaccharidosis type 2: This Phase 1/2 clinical trial attempts to treat MPS II (mucopolysaccharidosis II) patients with mutations in the iduronate-2-sulfatase (IDS) gene by inserting a correct copy of the IDS gene into the albumin locus in hepatocytes.